UroGen Pharma Ltd. URGN

Rank #1899 · Nasdaq · $1.6B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

39.3

P/E

-12.6

P/B

-24.45

ROE

194.6%

Op. Margin

-107.1%

Debt Ratio

-452%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -12.6x, P/B -24.45x. Ranks in the top 90% of the universe.

Profitability ★★★☆☆

Average

ROE 194.6%. Ranks in the top 46% of the universe.

Safety ★★★★★

Excellent

Debt ratio -452%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆

Good

Revenue growth of 9.3% year over year. Ranks in the top 36% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2018	$0.0B	$0.0B	$-0.0B	$0.0B	4.6	43
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	-244.5	83
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	-608211.1	25
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	-1074.2	14
2022	$0.0B	$-0.1B	$-0.1B	$0.1B	-192.1	116
2023	$0.1B	$-0.1B	$-0.1B	$0.0B	-122.8	2674
2024	$0.1B	$-0.1B	$-0.1B	$-0.1B	-79.2	-273
2025	$0.1B	$-0.1B	$-0.1B	$-0.1B	-107.1	-452

← See the full screener